. . .The deal would value Verona at $107 per American depositary share, the report said, citing three sources familiar with the negotiations. That represents a 23% premium to its Tuesday’s closing price.
Verona Pharma is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases (COPD), with Ohtuvayre (ensifentrine) its first commercial product. . . .
Yep. . . dead Midsummer days seem to spawn the occasional deal rumor. Onward. It will, of course, complement the Winrevair™ franchise. . . . But what of Trump's new threat to charge non-US pharma a 200% price tariff for importing to the US?! How can one defend this price, if the corrupt clown persists in his. . . lunacy?!
नमस्ते
2 comments:
The takeover was announced this morning.
Indeed. I get that it is a complementary therapy to that already on market at Merck in Winrevar. . . I’m just a little surprised at the price, given Trump’s tariff sabre rattling.
Will importing the COPD drug incur a 200% tariff in the US?
What a silly time this is — in US politics.
Thanks and. . . Namaste!
Post a Comment